Jazz Pharmaceuticals PLC - יחס שווי פעילות למכירות JAZZ

לוגו של חברה ציבורית Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals minimizes industry threats by combining sleep disorder therapies with the development of oncology and rare diseases. The EV/Sales multiple confirms the resilience of this strategy, with 3807.89 serving as the current level of the metric. Profitability is based on patent protection and Xanidatamab margins, while a powerful cash flow is driven by sales of Rylaze and sodium oxybate.

Jazz Pharmaceuticals PLC (JAZZ): יחס שווי פעילות להכנסות מ-23.11.2025 עד 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Jazz Pharmaceuticals plc (JAZZ)

הערכת שווי פונדמנטלית:Jazz Pharmaceuticals plc
מוצר סדרתי של jazzpharma.com

This indicator compares the total enterprise value, adjusted for net debt, against the volume of generated revenue, allowing for an assessment of the market value of one dollar of sales regardless of the financing structure. Given the monopoly position of Jazz Pharmaceuticals (JAZZ) in the narcolepsy therapy segment and the stringent regulatory barriers for competitors, the current EV/Sales value reflects a premium for high cash flow stability and the protected nature of the business model.